Management of acutely ill patients in the hospital setting: focus on quetiapine

References

• Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP. The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med 2001;1–88.
   PubMed Web of Science ®Google Scholar
• Allen MH, Carpenter D, Sheets JL, Miccio S, Ross R. What do consumers say they want and need during a psychiatric emergency?. J Psychiatr Pract 2003; 9: 39–58
   PubMedGoogle Scholar
• McGorry PD, Chanen A, McCarthy, Van Riel R, McKenzie D, Singh BS. Posttraumatic stress disorder following recent-onset psychosis. An unrecognized postpsychotic syndrome. J Nerv Ment Dis 1991; 179: 253–8
   PubMed Web of Science ®Google Scholar
• Meyer H, Taiminen T, Vuori T, Aijala A, Helenius H. Posttraumatic stress disorder symptoms related to psychosis and acute involuntary hospitalization in schizophrenic and delusional patients. J Nerv Ment Dis 1999; 187: 343–52
   PubMed Web of Science ®Google Scholar
• Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berlin) 2004; 171: 121–32
   PubMed Web of Science ®Google Scholar
• Lambert M, Schimmelmann BG, Karow A, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs – concepts, measurement and clinical relevance. Pharmacopsychiatry 2003; 36(Suppl 3)181–90
   PubMed Web of Science ®Google Scholar
• Van Putten T, May PRA. Subjective response as a predictor of outcome in pharmacotherapy. The consumer has a point. Arch Gen Psychiatry 1978; 35: 477–80
   PubMed Web of Science ®Google Scholar
• Van Putten T, May PR, Marder SR, Wittmann LA. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38: 187–90
   PubMed Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892–909
   PubMed Web of Science ®Google Scholar
• National Institute of Clinical Excellence. Core interventions in the treatment and management of schizophrenia in primary and secondary care (Clinical Guideline 1). 2004 [ http://www.nice.org.uk].
   Google Scholar
• SBMHT. Rapid tranquillisation in the management of a risk of imminent violence among psychiatric inpatients 2004 [ http://www.ukppg.org.uk/04-rt-birmingham-forensic.pdf].
   Google Scholar
• Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP. Treatment of behavioral emergencies: the expert consensus guidelines series. J Psychiatr Pract 2005; 11(Suppl 1)5–25
   PubMedGoogle Scholar
• Mohr P, Pecenak J, Svestka J, Swingler D, Treuer T. Treatment of acute agitation in psychotic disorders. Neuro Endocrinol Lett 2005; 26: 327–35
   PubMed Web of Science ®Google Scholar
• Currier G. Atypical antipsychotic medications in the psychiatric emergency service. J Clin Psychiatry 2000; 61(Suppl. 14)21–26
   PubMed Web of Science ®Google Scholar
• Cunane JG. Drug management of disturbed behaviour by psychiatrists. Psychiatr Bull 1994; 18: 138–139
   Google Scholar
• Huf G, da Silva Freire Coutinho E, Fagundes HM, Jr, et al. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janiero – Brazil: a prevalence study. BMC Psychiatry 2002; 2: 4
   PubMed Web of Science ®Google Scholar
• Allen MH, Currier GW, Hughes DH, Docherty JP, Carpenter D, Ross R. Treatment of behavioral emergencies: a summary of the expert consensus guidelines. J Psychiatr Pract 2003; 9: 16–38
   PubMedGoogle Scholar
• Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol 1999; 6: 69–83
   PubMedGoogle Scholar
• Chong S-A, Remington G. Clozapine augmentation: safety and efficacy. Schizophr Bull 2000; 26: 421–40
   PubMed Web of Science ®Google Scholar
• Swift R, Davidson D, Rosen S, Fitz E, Camara P. Naltrexone effects on diazepam intoxication and pharmacokinetics in humans. Psychopharmacology (Berlin) 1998; 135: 256–62
   PubMed Web of Science ®Google Scholar
• Goldstein J, Zhong K. Tolerance to somnolence with quetiapine (“Seroquel”): preclinical mechanisms and clinical evidence. Int J Neuropsychopharmacol 2004;7(Suppl 2):S411–12, abs P02.410.
   Google Scholar
• Barnes TR, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol 1998; 13(Suppl 3)S49–S57
   PubMedGoogle Scholar
• Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002; 14: 47–57
   PubMedGoogle Scholar
• Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43: 135–45
   PubMed Web of Science ®Google Scholar
• Kasper S. Treatment challenges in the acute hospital setting. World J Biol Psychiatry 2005; 6: 210–1
   PubMed Web of Science ®Google Scholar
• Kane JM, Leucht S, Carpenter D, Docherty JP. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Medication selection, dosing, and dose equivalence. J Clin Psychiatry 2003; 64(Suppl 12)21–51
   PubMed Web of Science ®Google Scholar
• Currier GW, Chou JC, Feifel D, Bossie CA, Turkoz I, Mahmoud RA, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004; 65: 386–94
   PubMed Web of Science ®Google Scholar
• Hovens JE, Dries PJ, Melman CT, Wapenaar RJ, Loonen AJ. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. J Psychopharmacol 2005; 19: 51–7
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Ahl J, Rotelli MD, McMullen E. Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. Am J Emerg Med 2004; 22: 181–6
   PubMed Web of Science ®Google Scholar
• Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158: 1149–51
   PubMed Web of Science ®Google Scholar
• Brook S, Lucey JV, Gunn KP, for the Ziprasidone I.M. Study Group. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry 2000; 61: 933–41
   PubMed Web of Science ®Google Scholar
• Preval H, Klotz SG, Southard R, Francis A. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry 2005; 27: 140–4
   PubMed Web of Science ®Google Scholar
• Modell S, Wilber R, Marcus R, , et al. Efficacy and safety of intramuscular aripiprazole. Poster presented at the 12th Congress of the Association of European Psychiatrists, Geneva, Switzerland, 14–18 April, 2004.
   Google Scholar
• Chengappa KNR, Goldstein JM, Greenwood M, John V, Levine J. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 2003; 25: 530–41
   PubMed Web of Science ®Google Scholar
• Arango C, Bernardo M. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum Psychopharmacol 2005; 20: 237–41
   PubMed Web of Science ®Google Scholar
• Ducci G, Accorra D. Evaluation of clinical efficacy and tolerability of the switch from anti-psychotic treatment by injection to orally with quetiapine. Poster presented at the 10th Congress of the Italian Society of Psychopathology, Rome, 22–26 February, 2005.
   Google Scholar
• Small JG, Kolar MC, Kellams JJ. Quetiapine in schizophrenia: onset of action within the first week of treatment. Curr Med Res Opin 2004; 20: 1017–23
   PubMed Web of Science ®Google Scholar
• Ganesan S, Levy M, Bilsker D, Khanbhai I. Effectiveness of quetiapine for the management of aggressive psychosis in the emergency psychiatric setting: a naturalistic uncontrolled trial. Int J Psychiatry Clin Pract 2005; 9: 199–203
   PubMed Web of Science ®Google Scholar
• Keks N, Tonso M, Tabone K, et al. Clinical experience with atypical antipsychotics in an acute inpatient unit: focus on quetiapine. Int J Psychiatry Clin Pract. 2006; 10(2)138–141
   PubMed Web of Science ®Google Scholar
• Smith MA, McCoy R, Hamer-Maansson J, Brecher M. Rapid dose escalation with quetiapine: a pilot study. J Clin Psychopharmacol 2005; 25: 331–5
   PubMed Web of Science ®Google Scholar
• Kasper S, Konstantinidis A, Kindler J, et al. Rapid initiation of quetiapine in acutely ill patients with schizophrenia or schizoaffective disorder. European Psychiatry 2006; 21(Suppl 1)S102
   PubMed Web of Science ®Google Scholar
• Pae CU, Kim TS, Kim JJ, et al. Rapid versus conventional titration of quetiapine in acute schizophrenia. Eur Neuropsychopharmacol 2005; 15: S505
   PubMed Web of Science ®Google Scholar
• Boidi G. Safety and tolerability of rapid versus conventional dose escalation with quetiapine in acute schizophrenia and schizoaffective disorder: a randomised, multicentre, parallel-group, open trial. Poster presented at the 14th European Congress on Psychiatry, Nice, France, 4–8 March, 2006.
   Google Scholar
• Oral T, Ozerdem A, Vahip S, Yazici O. Rapid titration of quetiapine in acute manic patients: a case series. Eur Neuropsychopharmacol 2005; 15: S488
   Web of Science ®Google Scholar
• Sanger TM, Tohen M, Vieta E, et al. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord 2003; 73: 155–61
   PubMed Web of Science ®Google Scholar
• Pae CU, Nassir GS, Kim TS, et al. Rapid titration versus conventional titration of quetiapine in the treatment of bipolar mania: a preliminary trial. Int Clin Psychopharmacol 2005; 20: 327–30
   PubMed Web of Science ®Google Scholar
• Seghers A, Ranalli E, Rijckmans V, Snauwaert P, Leven R, Parent M. Safety, tolerability, and efficacy of a rapid dose escalation of quetiapine in bipolar I mania – the FATIMA study. Eur Neuropsychopharmacol 2005; 15: S516
   Web of Science ®Google Scholar
• AstraZeneca. Seroquel® (quetiapine fumarate) tablets/US prescribing information 2005 [ http://www.astrazeneca-us.com/pi/Seroquel.pdf].
   Google Scholar
• Sacchetti E, Valsecchi P, Regini C, , et al. Comparison of quetiapine, olanzapine and risperidone in schizophrenia. Poster P.2.122 presented at the 17th Congress of the European College of Neuropsychopharmacology, Stockholm, Sweden, 9–13 October, 2004.
   Google Scholar
• Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004; 65: 1624–33
   PubMed Web of Science ®Google Scholar
• Mortimer A, Martin S, Loo H, Peuskens J. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004; 19: 63–9
   PubMed Web of Science ®Google Scholar
• Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161: 1837–47
   PubMed Web of Science ®Google Scholar
• Peuskens J, Bech P, Möller H-J, Bale R, Fleurot O, Rein W. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 1999; 88: 107–17
   PubMed Web of Science ®Google Scholar
• Perez V, Canas F, Tafalla M, Ovejero C, Rico-Villademoros F. Tolerability and effectiveness of quetiapine in inpatients with schizophrenia: results of the acute phase of the TESIS study. Eur Neuropsychopharmacol 2005; 15: S493
   Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO. Effectiveness of Antipsychotic Drugs on Patients with Chronic Schizophrenia. N Engl J Med 2005; 353: 1209–23
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006; 63: 1079–87
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Olanzapine Prescribing Information. Zyprexa® (olanzapine) tablets 2003 [ http://pi.lilly.com/us/zyprexa-pi.pdf].
   Google Scholar
• Risperdal® (risperidone) tablets/oral solution US prescribing information 2000 [ http://us.janssen.com/files/risperdal.pdf].
   Google Scholar
• Tandon R. Safety and tolerability: how do newer generation “atypical” antipsychotics compare?. Psychiatr Q 2002; 73: 297–311
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(Suppl 1)1–93
   PubMed Web of Science ®Google Scholar
• Keating AM, Aoun SL, Dean CE. Ziprasidone-associated mania: a review and report of 2 additional cases. Clin Neuropharmacol 2005; 28: 83–6
   PubMed Web of Science ®Google Scholar
• DeQuardo JR. Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?. J Clin Psychiatry 2004; 65: 132–3
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG, the Seroquel Trial 13 study group. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42 233–46.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE, Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351–60
   PubMed Web of Science ®Google Scholar
• American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596–601.
   Google Scholar
• Brecher M, Zukin S, Leong R, Osterling-Koskinen L, Jones M. Long-term weight change with quetiapine treatment in schizophrenia: a comprehensive data review. Neuropsychopharmacology 2004;29:S109, abst 114.
   Web of Science ®Google Scholar
• Mullen J, Jibson MD, Sweitzer D, the QUEST Study Group. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the Quetiapine Experience with Safety and Tolerability (QUEST) study. Clin Ther 2001;23:1839–54.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Elhaj O, Gajwani P, Gao K. Clinical highlights in bipolar depression: focus on atypical antipsychotics. J Clin Psychiatry 2005; 66(Suppl 5)26–33
   PubMed Web of Science ®Google Scholar
• Kasper S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety 2004; 20: 44–7
   PubMed Web of Science ®Google Scholar